Global Recombinant Human Thrombopoietin (rhTPO) Market Outlook 2022

Thrombopoietin (TPO), the major physiological regulator of platelet formation, binds to and activates TPO receptor on megakaryocytes, thereby promoting platelet production. Recombinant human thrombopoietin (rhTPO) is a novel therapeutic option for patients with immune thrombocytopenia (ITP) in China.

The global Recombinant Human Thrombopoietin (rhTPO) market was valued at US$ million in 2020 and is expected to reach US$ million by the end of 2027, growing at a CAGR of % during 2021-2027.
This report focuses on Recombinant Human Thrombopoietin (rhTPO) volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Recombinant Human Thrombopoietin (rhTPO) market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Global Recombinant Human Thrombopoietin (rhTPO) Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type
rhTPO
Fusion Protein

Segment by Application
Medication
Scientific Research

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

By Company
Qilu Pharmaceutical
R&D Systems
Merck
Shionogi
MedChemExpress
PeproTech
Kelun